The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: Vancomycin and linezolid

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 571-588

  Stein, Gary E ^a   Wells, Elizabeth M ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b PPSI   (United States)

Author keywords

Intrapulmonary concentration; Linezolid; Methicillin; Nosocomial pneumonia; Pharmacodynamics; Pharmacokinetics; Resistant Staphylococcus aureus; Skin infections; Tissue penetration; Vancomycin

Indexed keywords

AZTREONAM; LINEZOLID; VANCOMYCIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG ELIMINATION; DRUG PENETRATION; DRUG TISSUE LEVEL; HOSPITAL INFECTION; HUMAN; LUNG FLUID; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL PNEUMONIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; METHICILLIN RESISTANCE; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 76949105516     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903512057     Document Type: Review

References (97)

1. Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus. Arch Intern Med 1941;68:851-875
2. Blot SI, Vandewoude KH, Hoste EA, et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-2235
3. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-3862
4. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485
5. Glezen WP. Prevention and treatment of seasonal influenza. N Engl J Med 2008;359:2579-2585
6. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infection in children. Clin Infect Dis 2005;40:1785-1791
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674
8. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-317
9. Dahm RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus [published correction in N Engl J Med 2007; 357;1357]. N Engl J Med 2007;357:380-390
10. Moellering Jr RC. A 39-year-old man with a skin infection. JAMA 2008; 299:79-87
11. Skrupky LP, Micek ST, Kollef MH. Optimizing therapy for MRSA pneumonia. Sem Respir Crit Care Med 2007;28:615-623
12. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490
13. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-412
14. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992
15. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-1797
16. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394
17. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266
18. Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-766
19. Itani KMF, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus. Am J Surg 2009 (in press)
20. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-762
21. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006;42(Suppl 1):S51-7
22. Goldstein F. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 2007;59:1-4
23. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-1548
24. Kollef MH. Limitations of vancomycin in the management of resistant staphy-lococcal infections. Clin Infect Dis 2007;45(Suppl 3):S191-5
25. Chastre J, Fagon JY. Ventilator associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903
26. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-420
27. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474
28. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
29. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406
30. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S368-77
31. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044-4048
32. Centers for Disease Control and Prevention. Outpatient management of skin and soft tissue infections in the era of community-associated MRSA. Available at www.cdc.gov/mrsa/mrsa-initiative/skin-infection/mrsa-algorithm.html [Last accessed 28 October 2008]
33. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-282
34. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vanco-mycin. Clin Infect Dis 2006;42(Suppl 1):S35-9
35. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008;52:24-36
36. Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;37:1132-1136
37. Healy DP, Polk RE, Garson ML, et al. Comparison of steady-state pharmaco-kinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987;31:393-397
38. Cohen E, Dadashev A, Drucker M, et al. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002;49:155-160
39. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl S2):117-25
40. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775-2780
41. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmaco-dynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427-432
42. Islinger F, Dehghanyar P, Sauermann R, et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents 2006;27:108-112
43. Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22:91-97
44. Schentag JJ. Antimicrobial management strategies for gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001;29(4 Suppl): N100-7
45. Scheetz MH, Wunderink RG, Postelnick MJ, et al. Potential impact of vanco-mycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006;26:539-550
46. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S378-85
47. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008; 47:147-152
48. Brun-Buisson C, Lemaire F. Administration of antibiotics for pneumonia during respiratory failure: reaching the target. Am J Respir Crit Care Med 2001;164:1554-1555
49. Rello J, Mallol J. Optimal therapy for methicillin-resistant Staphylococcus aureus pneumonia: what is the best dosing regimen? Chest 2006; 130:938-940
50. Chiu LM, Amsden GW. Intrapulmonary pharmacokinetics of antibacterial agents. Am J Respir Med 2002;1:201-209
51. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 2007;7:498-504
52. Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008;61:235-237
53. Dykhuizen RS, Harvey G, Stephenson N, et al. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995;39:1842-1847
54. Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991;35:1947-1952
55. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992; 36:1171-1175
56. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992;36:1176-1180
57. Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of unbound line-zolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006;50:2455-2463
58. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-286
59. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-869
60. Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-388
61. Byl B, Jacobs F, Wallemacq P, et al. Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother 2003;47:2015-2017
62. Conte JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-1480
63. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003;51:1431-1434 [published erratum J Antimicrob Chemother 2003;52:536]
64. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetic and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005;33:1529-1533
65. Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and phar-macodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004;48:1441-1453 (Pubitemid 38544345)
66. Daschner FD, Frank U, Kummer A, et al. Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery. J Antimicrob Chemother 1987;19:359-362
67. Luzzati R, Sanna A, Allegranzi B, et al. Pharmacokinetics and tissue penetration of vancomycin in patients undergoing prosthetic mammary surgery. J Antimicrob Chemother 2000;45:243-245
68. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006;50:1372-1375
69. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-1846 (Pubitemid 32466358)
70. Lovering AM, Zhang J, Bannister GC, et al. Linezolid penetration into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-77
71. Dehghanyar P, Burger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005;49:2367-2371
72. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007;60:819-823
73. Majcher-Peszynska J, Haase G, Sass M, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64:1093-100. Published online 25 July 2008, doi:10.1007/s00228-008-0531-535
74. Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42(Suppl 1):S5-12
75. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-332
76. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiology and microbiological characteristics of infection caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States 1997-2001. Clin Infect Dis 2003;36:429-439
77. Miller D, Urdaneta V, Weltman A. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902
78. Sievert DM, Boulton ML, Stolzman G, et al. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-567
79. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health-Syst Pharm 2000;57(Suppl 2):S4-9 [correction in Am J Health-Syst Pharm 2001;58:78]
80. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-942
81. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2402
82. Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582-2586
83. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90
84. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16:S31-4
85. Fowler Jr VG, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004;190:1140-1149
86. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-1705
87. Lam AP, Wunderink RG. Methicillin-resistant S. aureus ventilator-associated pneumonia: strategies to prevent and treat. Semin Respir Crit Care Med 2006;27:92-103
88. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement. M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute, 2006
89. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin treatment for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006;166:2138-2144
90. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-1336
91. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-955
92. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-1115
93. Jones RN, Ross JE, Fritsche TR, et al. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006;57:279-287
94. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007;59:309-317
95. Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER program for 2007). Diagn Microbiol Infect Dis 2008;62:416-426
96. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of jS-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003;17:479-501
97. Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-3489